EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Francesco Zaccardi, Vanita R Aroda iD, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney iD, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J Davies

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5787-5802

DOI: 10.1111/dom.70770 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.04.2026. Verfasst von Francesco Zaccardi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk, National Institute for Health and Care Research (NIHR), NIHR Leicester Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA 1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to placebo and active comparators, according to age at study enrolment. This study also assessed aggregated safety data across age subgroups. Materials and Methods This post hoc analysis of the SUSTAIN (once‐weekly subcutaneous administration) and PIONEER (once‐daily oral administration) programmes assessed the efficacy of semaglutide treatment in different age subgroups by comparing change in HbA 1c and BW between young adults with T2D (≤ 40 years), middle‐aged adults with T2D (> 40‐ ≤ 50 years), and middle older‐aged adults with T2D (> 50 years). Selected safety outcomes were assessed, focusing on serious adverse events (SAEs) and gastrointestinal SAEs from the programmes.

Results

Findings indicate a reduction in HbA 1c levels and BW in participants across all age subgroups that were treated with semaglutide, particularly in young adults versus other age subgroups. The proportion of participants experiencing SAEs was overall comparable between semaglutide treatment and comparators across age subgroups and administration route.

Conclusions

Semaglutide shows notable and consistent efficacy in reducing HbA 1c and BW across all age subgroups with T2D, including young adults. Effective glucose‐ and weight‐lowering interventions in people living with T2D at an earlier stage in life may reduce the high risk of future health complications associated with developing T2D as a younger adult.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsHumansSemaglutideAdultFemaleGlycated HemoglobinMaleMiddle AgedYoung AdultTreatment OutcomeBody WeightBlood GlucoseAge FactorsAdministration, OralInjections, Subcutaneous

Stichwörter der Autor:innen

GLP‐1cohort studyglycaemic controlmeta‐analysissemaglutidetype 2 diabetes

Substanzen

SemaglutideGlucagon-Like PeptidesHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, humanBlood Glucose

Autor:innen und Institutionen

  • Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK.
  • Diabetes Research Centre, University of Leicester, Leicester, UK.
  • Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Novo Nordisk A/S, Søborg, Denmark.
  • NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Novo Nordisk GBS, Bengaluru, India.

ORCID-Profile: Vanita R Aroda, Jonathan Goldney

Förderung

  • Novo Nordisk
  • National Institute for Health and Care Research (NIHR)
  • NIHR Leicester Biomedical Research Centre
  • Wellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme

Zitieren

APA

Zaccardi, F., Aroda, V. R., Arslan, E. G., Bardtrum, L., Goldney, J., Ising, E., Priyadarshini, P., Slater, T., & Davies, M. J. (2026). Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials. Diabetes, Obesity and Metabolism, 28(7), 5787-5802. https://doi.org/10.1111/dom.70770

Vancouver

Zaccardi F, Aroda VR, Arslan EG, Bardtrum L, Goldney J, Ising E, et al. Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials. Diabetes, Obesity and Metabolism. 2026;28(7):5787-5802. doi:10.1111/dom.70770

BibTeX
@article{Zaccardi2026,
  author = {Zaccardi, Francesco and Aroda, Vanita R and Arslan, Ecenur Guder and Bardtrum, Lars and Goldney, Jonathan and Ising, Erik and Priyadarshini, Prachi and Slater, Tommy and Davies, Melanie J},
  title = {Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {5787--5802},
  doi = {10.1111/dom.70770}
}
Kostenlos starten →